Mesoblast (MESO) Net Cash Flow Growth (3y) (2019 - 2023)
Mesoblast (MESO) Net Cash Flow Growth (3y) (2019 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 38.47% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -30.66% |
| Mar 31, 2023 | 3.15% |
| Dec 31, 2022 | -33.86% |
| Sep 30, 2022 | 53.67% |
| Jun 30, 2022 | 6.74% |
| Mar 31, 2022 | -39.31% |
| Dec 31, 2021 | -43.69% |
| Sep 30, 2021 | -46.85% |
| Jun 30, 2021 | 0.40% |
| Mar 31, 2021 | 88.65% |
| Dec 31, 2020 | -27.14% |
| Sep 30, 2020 | -48.01% |
| Jun 30, 2020 | 69.76% |
| Mar 31, 2020 | -37.42% |
| Dec 31, 2019 | 56.30% |
| Sep 30, 2019 | 9.21% |
| Jun 30, 2019 | -3.22% |
| Mar 31, 2019 | 32.73% |